NCT07068490

Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100,000 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.

Detailed description

To evaluate the efficacy and safety of routine P-CAB use in patients with coronary artery disease who underwent PCI and maintain DAPT, as compared to guideline-directed proton pump inhibitor (PPI) usage.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Routine use of P-CAB on DAPT	This group received P-CAB with DAPT after PCI.
DRUG	Guideline Directed Medical Therapy	This group received PPI or not with DAPT after PCI according to GI bleeding risk.

Timeline

• Start date: 2024-10-22
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2025-07-16
• Last updated: 2025-07-16

Locations

1 site across 1 country: South Korea